Japan · Delayed Price · Currency is JPY PhoenixBio Statistics
Total Valuation
PhoenixBio has a market cap or net worth of JPY 1.23 billion. The enterprise value is 424.20 million.
| Market Cap | 1.23B |
| Enterprise Value | 424.20M |
Important Dates
The next confirmed earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
PhoenixBio has 4.07 million shares outstanding. The number of shares has increased by 0.48% in one year.
| Current Share Class | 4.07M |
| Shares Outstanding | 4.07M |
| Shares Change (YoY) | +0.48% |
| Shares Change (QoQ) | +0.00% |
| Owned by Insiders (%) | 19.47% |
| Owned by Institutions (%) | 6.35% |
| Float | 1.72M |
Valuation Ratios
The trailing PE ratio is 81.94.
| PE Ratio | 81.94 |
| Forward PE | n/a |
| PS Ratio | 0.86 |
| PB Ratio | 0.84 |
| P/TBV Ratio | 0.85 |
| P/FCF Ratio | 21.95 |
| P/OCF Ratio | 18.08 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 28.28 |
| EV / Sales | 0.30 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 7.57 |
Financial Position
The company has a current ratio of 4.20, with a Debt / Equity ratio of 0.20.
| Current Ratio | 4.20 |
| Quick Ratio | 3.24 |
| Debt / Equity | 0.20 |
| Debt / EBITDA | n/a |
| Debt / FCF | 5.34 |
| Interest Coverage | -8.75 |
Financial Efficiency
Return on equity (ROE) is 1.06% and return on invested capital (ROIC) is -3.23%.
| Return on Equity (ROE) | 1.06% |
| Return on Assets (ROA) | -1.02% |
| Return on Invested Capital (ROIC) | -3.23% |
| Return on Capital Employed (ROCE) | -2.05% |
| Weighted Average Cost of Capital (WACC) | 5.19% |
| Revenue Per Employee | 25.87M |
| Profits Per Employee | 272,727 |
| Employee Count | 55 |
| Asset Turnover | 0.66 |
| Inventory Turnover | 1.11 |
Taxes
In the past 12 months, PhoenixBio has paid 6.00 million in taxes.
| Income Tax | 6.00M |
| Effective Tax Rate | 28.57% |
Stock Price Statistics
The stock price has decreased by -28.91% in the last 52 weeks. The beta is 0.36, so PhoenixBio's price volatility has been lower than the market average.
| Beta (5Y) | 0.36 |
| 52-Week Price Change | -28.91% |
| 50-Day Moving Average | 339.22 |
| 200-Day Moving Average | 421.98 |
| Relative Strength Index (RSI) | 25.09 |
| Average Volume (20 Days) | 7,295 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, PhoenixBio had revenue of JPY 1.42 billion and earned 15.00 million in profits. Earnings per share was 3.69.
| Revenue | 1.42B |
| Gross Profit | 1.07B |
| Operating Income | -35.00M |
| Pretax Income | 21.00M |
| Net Income | 15.00M |
| EBITDA | -750,000 |
| EBIT | -35.00M |
| Earnings Per Share (EPS) | 3.69 |
Balance Sheet
The company has 1.10 billion in cash and 299.00 million in debt, with a net cash position of 805.00 million or 197.78 per share.
| Cash & Cash Equivalents | 1.10B |
| Total Debt | 299.00M |
| Net Cash | 805.00M |
| Net Cash Per Share | 197.78 |
| Equity (Book Value) | 1.46B |
| Book Value Per Share | 359.44 |
| Working Capital | 1.16B |
Cash Flow
In the last 12 months, operating cash flow was 68.00 million and capital expenditures -12.00 million, giving a free cash flow of 56.00 million.
| Operating Cash Flow | 68.00M |
| Capital Expenditures | -12.00M |
| Depreciation & Amortization | 34.25M |
| Net Borrowing | -69.00M |
| Free Cash Flow | 56.00M |
| FCF Per Share | 13.76 |
Margins
Gross margin is 74.98%, with operating and profit margins of -2.46% and 1.05%.
| Gross Margin | 74.98% |
| Operating Margin | -2.46% |
| Pretax Margin | 1.48% |
| Profit Margin | 1.05% |
| EBITDA Margin | -0.05% |
| EBIT Margin | -2.46% |
| FCF Margin | 3.58% |
Dividends & Yields
PhoenixBio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.48% |
| Shareholder Yield | -0.48% |
| Earnings Yield | 1.22% |
| FCF Yield | 4.56% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
PhoenixBio has an Altman Z-Score of 1.76 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.76 |
| Piotroski F-Score | 7 |